Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.

Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL.

Ann Intern Med. 2001 Feb 20;134(4):261-6.

PMID:
11182835
2.

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.

Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL.

JAMA. 2000 Apr 5;283(13):1703-9.

PMID:
10755496
3.

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.

Gardin JM, Weissman NJ, Leung C, Panza JA, Fernicola D, Davis KD, Constantine GD, Reid CL.

JAMA. 2001 Oct 24-31;286(16):2011-4.

PMID:
11667938
4.

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.

Ryan DH, Bray GA, Helmcke F, Sander G, Volaufova J, Greenway F, Subramaniam P, Glancy DL.

Obes Res. 1999 Jul;7(4):313-22.

5.

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.

Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ.

Am J Cardiol. 1999 Dec 1;84(11):1335-8.

PMID:
10614800
7.

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.

Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS.

Ann Intern Med. 1998 Dec 1;129(11):870-4. Erratum in: Ann Intern Med 2000 Jan 18;132(2):167.

PMID:
9867728
8.
9.

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.

Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT.

N Engl J Med. 1998 Sep 10;339(11):713-8.

10.

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.

Sachdev M, Miller WC, Ryan T, Jollis JG.

Am Heart J. 2002 Dec;144(6):1065-73. Review.

PMID:
12486432
11.

Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment.

Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT.

J Am Coll Cardiol. 1999 Dec;34(7):2088-95.

12.

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.

Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE.

N Engl J Med. 1998 Sep 10;339(11):719-24.

13.

Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.

Burger AJ, Charlamb MJ, Singh S, Notarianni M, Blackburn GL, Sherman HB.

Int J Cardiol. 2001 Jul;79(2-3):159-65.

PMID:
11461737
14.

Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.

Palmieri V, Arnett DK, Roman MJ, Liu JE, Bella JN, Oberman A, Kitzman DW, Hopkins PN, Morgan D, de Simone G, Devereux RB.

Am J Med. 2002 Jun 15;112(9):710-5.

PMID:
12079711
15.

Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation.

Mast ST, Gersing KR, Anstrom KJ, Krishnan KR, Califf RM, Jollis JG.

Am J Cardiol. 2001 Apr 15;87(8):989-93: A4.

PMID:
11305992
16.

Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.

Maréchaux S, Jeu A, Jobic Y, Ederhy S, Donal E, Réant P, Abouth S, Arnasteen E, Boulanger J, Ennezat PV, Garban T, Szymanski C, Tribouilloy C.

Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):349-56. doi: 10.1016/j.acvd.2013.04.006. Epub 2013 May 31.

17.

Operation for anorexigen-associated valvular heart disease.

Caccitolo JA, Connolly HM, Rubenson DS, Orszulak TA, Schaff HV.

J Thorac Cardiovasc Surg. 2001 Oct;122(4):656-64.

18.

Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.

Teramae CY, Connolly HM, Grogan M, Miller FA Jr.

Mayo Clin Proc. 2000 May;75(5):456-61.

PMID:
10807073
19.

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.

Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T.

Circulation. 2000 May 2;101(17):2071-7.

20.

[Valvular regurgitation caused by anorectic agents].

Melero Tejedor JM, Rodríguez Bailón I, Such Martínez M, Porras Martín C, Olalla Mercadé E, Espinosa Caliani JS.

Rev Esp Cardiol. 2000 Dec;53(12):1667-70. Spanish.

Supplemental Content

Support Center